Status:
COMPLETED
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Lead Sponsor:
Pfizer
Conditions:
Arthritis Rheumatoid
Eligibility:
All Genders
18+ years
Brief Summary
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
Eligibility Criteria
Inclusion
- RA patients in Corrona initiating tofacitinib or a TNF biologic (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) after 06 November 2012 (market approval of Tofacitinib) during follow-up in Corrona with no prior use of tofacitinib. Only the patient's first initiation after 06 November 2012 will be included in the analysis
- Have a 6 and / or 12-month follow-up visit (with +/- 2 month window)
- Have Clinical Disease Activity Index (CDAI) measures at baseline and at the follow-up visit
Exclusion
- Patients who have not failed methotrexate (MTX) or another csDMARD (ie 1st line initiators)
Key Trial Info
Start Date :
January 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 29 2021
Estimated Enrollment :
7807 Patients enrolled
Trial Details
Trial ID
NCT04721821
Start Date
January 22 2021
End Date
November 29 2021
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10017